JPRN-UMIN000004310已完成2 期
Efficacy of mFOLFOX6 with bebacizumab or cetuximab based on K-ras status for unresectable hepatic metastasis of colorectal cancer - Efficacy of mFOLFOX6 with bebacizumab or cetuximab based on K-ras status for unresectable hepatic metastasis of colorectal cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Brain metastasis, brain tumor 2. symptomatic cerebrovascular disease 3. active bleeding 4. uncontrolled hypertention etc.
研究者
相似试验
招募中
2 期
Phase II study of Cetuximab with mFOLFOX6 treatment in patients with previously untreated Rectal cancerRectal CancerJPRN-UMIN000010791PO FMPC (Future Medicine Promoting Consortium)25
Unknown
2 期
Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer PatientsLiver MetastasesColorectal CancerNCT01322178Fudan University90
招募中
2 期
mFOLFOX6+Cetuximab in Treating Patients With not Optimally Resectable Liver Metastases From Colorectal Cancerliver metastases from colorectal cancerJPRN-UMIN000004811Cancer Institute Hospital of Japanese Foundation for Cancer Research45
已完成
2 期
Safety and efficacy of FOLFOX plus bevacizumab or FOLFIRI plus bevacizumab as second line Therapy in Advanced colorectal Cancer previously treated with bevacizumab.JPRN-UMIN000002378Japan South West Oncology Group45
进行中（未招募）
1 期
Bi-weekly Cetuximab combined with FOLFOX-6 as first-line treatment in metastatic colorectal cancer patients with wild-type k-ras status - CEBIFOXEUCTR2007-000460-24-DEniversity of Duisburg-Essen